Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results
Date:2/16/2010

n, compared to $28.9 million for 2008.  The year-over-year decrease in G&A expenses is primarily due to decreased commercial and marketing expenses relating to Fanapt™.
  • Employee stock-based compensation expense recorded in the fourth quarter of 2009 totaled $2.4 million.  Of these non-cash charges, $0.5 million was recorded as R&D expense and $1.9 million was recorded as G&A expense.  For the third quarter of 2009 and the fourth quarter of 2008, total stock-based compensation expense was $3.3 million and $0.7 million, respectively.  The decrease in stock-based compensation expense in the fourth quarter of 2009 relative to the third quarter of 2009 is the result of the full vesting of non-qualified options issued at a higher fair market value.  The increase in stock-based compensation expense in the fourth quarter of 2009 relative to the fourth quarter of 2008 is primarily due to a lower stock-based compensation expense resulting from the workforce reduction in the fourth quarter of 2008.  For the full year of 2009, total stock-based compensation was $10.8 million, compared to $13.4 million for 2008.  

  • Cash and marketable securities increased by $184.6 million during the fourth quarter of 2009.  Changes included $9.2 million of net losses, the payment of the $5.0 million balance due to Novartis for the milestone payment relating to the FDA's approval of the NDA for Fanapt™ and increases in other working capital of $1.9 million'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Vanda Pharmaceuticals Reports Second Quarter 2009 Results
2. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
3. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
4. Vanda Pharmaceuticals Reports First Quarter 2009 Results
5. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
6. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
7. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
8. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
9. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
10. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
11. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, ... novel pathogen-specific therapies for serious infections and diseases, announced ... issued a Notice of Allowance for a composition of ... C. difficile program, SYN-004. This is Synthetic ... in the U.S. and adds to the Company,s extensive ...
(Date:10/22/2014)... -- Nuvilex, Inc. (OTCQB: NVLX) – According to the ... living with diabetes, with  that number expected to grow ... for diabetes treatments is approximately $500 billion.  ... pancreatic cancer.  Pancreatic cancer is the fourth most common ... the United States , and according to a ...
(Date:10/22/2014)... and HONG KONG , Oct. 22, ... therapeutics enterprise, announced today that rare disease expert ... vice president, research. Dr. McKew brings more than two ... positions at the National Institutes of Health, Wyeth Research ... Wyeth). Dr. McKew will lead aTyr,s efforts to expand and ...
(Date:10/20/2014)... Oct. 20, 2014 Mapp Biopharmaceutical,s valiant ... antibody therapeutic to fight the Ebola outbreak will ... time-consuming the production of pharmaceuticals can be, according ... said that while some may be taken aback ... those with industry knowledge are well aware of ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... Web addicts, take heart: A public-private effort is moving ... , AOL-SkyCable has been chosen to enter negotiations ... for the general public. The "Wireless Wisconsin" service would ... Madison and the Dane County Regional Airport. The project ...
... Information-technology businesses are taking apart their processes ... 2005 CEO-CIO Symposium on Wednesday just around the ... offered their opinions on how the state and its ... year progresses. , Restructuring and rebuilding ,According to ...
... Johnson Controls Inc. has completed ... a French company, Valeo. Valeo is based in ... million) for the business, headquartered in Pontoise, France, ... engines. Johnson Controls bought the division from another ...
Cached Biology Technology:Madison wi-fi plans move ahead 2Restructuring is a watchword for IT in 2005 2Restructuring is a watchword for IT in 2005 3
(Date:10/22/2014)... 20, 2014 The Nano-Bio Manufacturing Consortium (NBMC), ... Research Laboratory (AFRL), has chosen a project proposed by ... University of Arizona College of Medicine – ... project,s goal is to assess different sweat collection methods ... of sweat under a variety of human-body conditions, the ...
(Date:10/18/2014)... patients referred for evaluation of suspected genetic conditions, ... 25 percent, including detection of a number of ... disease, according to a study appearing in ... coincide with the American Society of Human Genetics ... or coding regions of thousands of genes simultaneously ...
(Date:10/17/2014)... To date, antidotes ... doctors are often limited to supportive therapy such as induced ... of drugs involved. So what can be done if a ... professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences at ... "The task was to develop an agent that could eliminate ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3Whole-exome sequencing shows potential as diagnostic tool 2Emergency aid for overdoses 2Emergency aid for overdoses 3
... SAN FRANCISCO An increasing number of obese adolescents, ... case study presented Sunday, Oct. 3, at the American ... San Francisco, highlights the possible link between gastric bypass ... neural tube defects, which can lead to varying degrees ...
... of private health insurance and its consequent lack of ... with uterine cancer and may partly explain the mortality ... data presented at the Third AACR Conference on The ... twice as likely to die within four years compared ...
... breast cancer that lacked estrogen and progesterone receptors and did ... those with other types of invasive breast cancer, according to ... Science of Cancer Health Disparities, held Sept. 30 Oct. ... in Puerto Rico, following U.S. trends, it is important to ...
Cached Biology News:Loss of nutrients following gastric bypass surgery in adolescent girls 2Lack of private health insurance impacted cancer survival 2Decreased survival for Puerto Rican women with 'triple-negative' breast cancer subtype 2
Mouse monoclonal [1241] to Parainfluenza Virus type 2...
Mouse monoclonal [0.N.509] to PCTAIRE2 ( Abpromise for all tested applications). entrezGeneID: 5128 SwissProtID: Q00537...
Parathyroid Hormone Receptor 2 [PTHR2]...
... the caudal-related homeobox family, is an intestine-specific ... differentiation in intestinal epithelial cells. It plays ... the phenotype of differentiated villus enterocytes as ... phenotype. Clone CDX2-88 reacts with a conserved ...
Biology Products: